Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Early Tislelizumab May Boost PFS in Esophageal Cancer

2.

BMTs that are "half-matched" are effective in treating severe sickle cell disease.

3.

Despite reports of hundreds of cancer cases, carcinogens have been discovered at nuclear missile sites in Montana.

4.

Obesity-associated cancers may be on the rise in Puerto Rico

5.

Chris Hoy reveals that he has terminal cancer?here's how to spot early signs of prostate cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot